

21 March 2019

Scancell Holdings Plc
("Scancell" or the "Company")

Professor Lindy Durrant receives Waldenström award from the Swedish Society of Oncology

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is delighted to announce that Professor Lindy Durrant, Scancell's Chief Scientific Officer, is to receive the Swedish Society of Oncology's Waldenström award. Professor Durrant will be presented with the award at the Swedish Society of Oncology Annual Meeting on Thursday 21 March 2019 at 13:30 CET in Stockholm, Sweden, and will give an honorary lecture to fellow society members. The theme of the lecture will be on novel approaches to cancer vaccinations, including references to both ImmunoBody® and Moditope®, Scancell's novel immunotherapies for the treatment of cancer.

The Jan Waldenström award is presented for a successful career in cancer research. Waldenström macroglobulinemia is a type of non-Hodgkin lymphoma and is named after Jan Gösta Waldenström (17 April 1906–1 December 1996), the Swedish doctor of internal medicine, who first described the disease.

Professor Lindy Durrant, co-founder and Chief Scientific Officer of Scancell, is an internationally recognised immunologist in the field of tumour therapy. She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies and cancer vaccines. Lindy and her team have developed a platform called ImmunoBody®, which uses DNA encoding human antibodies engineered to express tumour antigens, to stimulate potent killer T cells for the treatment of melanoma and lung cancer. Her team is also the first group to show that immune responses to stress induced modifications, the Moditope® platform, induces strong anti-tumour responses. Lindy also has a personal chair in cancer immunotherapy at the University of Nottingham and has published over 200 original papers and patents.

Professor Lindy Durrant, Chief Scientific Officer of Scancell, said:

"I am honoured to have been awarded the prestigious Waldenström award which recognises the research my group has undertaken and its potential application to the treatment of cancer. I am proud to be leading the research at Scancell, developing products that stimulate the immune system to treat or prevent cancer recurrence and for our work to be recognised by the Swedish Society of Oncology."

For Further Information:

Scancell Holdings Plc

Dr John Chiplin, Chairman
Dr Cliff Holloway, CEO

+44 (0) 20 3727 1000

Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate broker)

Freddy Crossley/Emma Earl

+44 (0) 20 7886 2500

FTI Consulting

Simon Conway/Natalie Garland-Collins

+44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

- Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

For further details, please see our website: www.scancell.co.uk